Of note, our results support that the anti-tumor immune effects induced by trastuzumab and pertuzumab are independent of the trastuzumab sensitivity profile of HER2+ cancer cells, as seen by the immune activation and cytotoxicity induced against the trastuzumab-resistant HCC1954 cell line (Figure 4, Supplementary Figures 3 and 5) (65, 89, 91). Here, ERBB2 is linked to cancer.